Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Toca 511 + Toca FC |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Toca 511 | T5.0002|Vocimagene Amiretrorepvec | Chemotherapy - Antimetabolite 14 | Vocimagene Amiretrorepvec (Toca 511) is a retroviral vector encoding yeast cytosine deaminase, which converts the prodrug flucytosine into 5-fluorouracil upon infection of tumor cells, leading to tumor cell death (PMID: 22547150, PMID: 30676111). | |
Toca FC | Chemotherapy - Antimetabolite 14 | Toca FC is an extended release form of flucytosine, which inhibits DNA synthesis after conversion to 5-fluorouracil (PMID: 30676111). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT01156584 | Phase I | Toca 511 + Toca FC | A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma | Completed | USA | 0 |
NCT02414165 | Phase II | Bevacizumab Lomustine Toca 511 + Toca FC Temozolomide | P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) | Terminated | USA | CAN | 2 |